Macro Finance
Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials
Bloomberg Markets·October 9, 2026·1 min read
Bambusa Therapeutics Inc. filed for an initial public offering to help fund trials of its drugs to treat eczema and other inflammation disorders. The company plans to use the proceeds from the IPO to advance its pipeline of dermatology treatments. Bambusa has not yet set a price range or timeline for the offering.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.